Gyon Technologies Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gyon Technologies Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,837	Closed	-$545K	–	654
2022 Q2	$545K	Buy	6,837 +4,595	+205%	+$435K	0.15%	158
2022 Q1	$236K	Sell	2,242 -6,953	-76%	-$678K	0.17%	209
2021 Q4	$991K	Buy	9,195 +5,593	+155%	+$610K	0.18%	158
2021 Q3	$395K	Buy	+3,602	New	+$374K	0.11%	238
2021 Q1	–	Sell	-4,963	Closed	-$363K	–	550
2020 Q4	$363K	Buy	+4,963	New	+$369K	0.12%	229

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Gyon Technologies Capital Management's HZNP Position: Q3 2022 in Review

Gyon Technologies Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 6,837 shares — an estimated $545K sold.

Gyon Technologies Capital Management first reported a position in HZNP in Q4 2020 and held it in 5 quarters. The position peaked at $991K in Q4 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Gyon Technologies Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Gyon Technologies Capital Management sold 6,837 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $545K.
Gyon Technologies Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 5 quarters.
Gyon Technologies Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $991K in Q4 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.